An educational overview of medicinal cannabis, the current scientific evidence and important safety considerations.
Cannabis has a long history of use in different cultures, including traditional medicinal practices. In recent decades, scientific research has examined the cannabis plant, its chemical compounds and their possible applications in modern medicine.
In Australia, medicinal cannabis is regulated within the healthcare system and may be prescribed by appropriately qualified healthcare professionals under applicable regulatory requirements.
However, the scientific evidence supporting medicinal cannabis varies considerably depending on the condition being studied, the formulation used and the outcomes measured.
Understanding both the potential benefits and the limitations of the available evidence is essential.
Medicinal cannabis refers to cannabis-derived products used for therapeutic purposes under medical supervision.
The cannabis plant contains numerous naturally occurring compounds, including cannabinoids and terpenes.
Two of the most extensively studied cannabinoids are:
Tetrahydrocannabinol (THC)
THC is a psychoactive cannabinoid that can affect perception, coordination, memory and other functions. It has been investigated for a range of therapeutic applications, but its use also carries potential adverse effects.
Cannabidiol (CBD)
CBD is another naturally occurring cannabinoid. It does not produce the characteristic intoxicating effects associated with THC, although it can still cause adverse effects and interact with other medicines.
Different medicinal cannabis formulations may contain THC, CBD or combinations of cannabinoids.
Their effects and safety profiles are not interchangeable.
Medicinal cannabis has been investigated for several forms of chronic pain, including neuropathic pain.
Some clinical studies have reported modest improvements in pain outcomes with certain cannabinoid-based treatments.
However, findings are inconsistent, the quality of evidence varies and adverse effects may limit suitability.
Medicinal cannabis should not be regarded as a universally effective treatment for chronic pain.
Researchers have investigated cannabinoids, particularly CBD, in relation to anxiety and other mental health conditions.
Although some early findings have generated scientific interest, the evidence remains insufficient to establish broad clinical effectiveness for anxiety or depression.
THC-containing products may also worsen anxiety or cause other psychiatric adverse effects in some individuals.
Further high-quality research is required.
Cannabinoids have been studied in relation to sleep quality, sleep duration and sleep disturbances associated with other health conditions.
Some studies have reported improvements in selected sleep outcomes, but findings remain uncertain and may not translate into sustained benefits.
Potential effects on daytime alertness, cognition and sleep patterns are important considerations.
One of the more established areas of cannabinoid research involves purified cannabidiol in certain severe epilepsy syndromes.
Specific pharmaceutical CBD preparations have demonstrated clinical benefits in defined patient populations.
These findings should not be generalised to all cannabis products or all forms of epilepsy.
Certain cannabinoid-based medicines have been investigated for nausea and vomiting associated with cancer chemotherapy.
Evidence and clinical recommendations vary by medicine and clinical circumstances.
Importantly, research into managing treatment-related symptoms should not be confused with evidence that cannabis treats cancer itself.
Researchers continue to investigate cannabinoids in relation to neurological conditions, inflammatory processes and other areas of medicine.
Many proposed applications remain experimental or supported by limited evidence.
Laboratory findings, animal studies and preliminary human research do not n